Last reviewed · How we verify
NCT06224621
Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy
NA trial testing Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy in 120 participants. Status unknown.
31 January 2026
Quick facts
| Lead sponsor | China National Center for Cardiovascular Diseases |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 31 January 2024 |
| Primary completion | 31 January 2026 |
| Estimated completion | 31 January 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Percutaneous Endocardial Septal Radiofrequency Ablation
Conditions studied
- Obstructive Hypertrophic Cardiomyopathy — all drugs for Obstructive Hypertrophic Cardiomyopathy →
Sponsor
China National Center for Cardiovascular Diseases — full company profile →
Who can join
Adults 18 to 85, any sex, with Obstructive Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, multicenter, single-arm objective performance criteria trial is designed to assess the efficacy and safety of the Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) procedure in the treatment of obstructive hypertrophic cardiomyopathy (oHCM). The primary objectives include investigating: 1. the treatment efficacy and safety of PESA treatment in oHCM patients with either left ventricular outflow tract obstruction (LVOTO) or midventricular obstruction; 2. the impact of PESA treatment on the functional capacity, quality of life and long-term prognosis of oHCM patients with either LVOTO or midventricular obstruction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06224621
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obstructive Hypertrophic Cardiomyopathy
Currently open trials in the same condition.
- NCT07023341 — A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic · Phase 3 · active not recruiting
- NCT06146660 — A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy · recruiting
- NCT06551129 — Real-world Patient Reported Outcomes Among Patients Treated With Camzyos · recruiting
- NCT06023186 — Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM · recruiting
- NCT05489705 — A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes · recruiting
Other China National Center for Cardiovascular Diseases trials
Trials by the same sponsor.
- NCT07514988 — Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment · NA · not yet recruiting
- NCT07476456 — Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death · not yet recruiting
- NCT07302659 — Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG · NA · recruiting
- NCT07482683 — Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach · not yet recruiting
- NCT06787430 — Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06224621 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China National Center for Cardiovascular Diseases
- Last refreshed: 20 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06224621.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing